Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NervGen Pharma Corp NGENF


Primary Symbol: V.NGEN

Healthcare
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a... see more

Recent & Breaking News (TSXV:NGEN)

Canadian Investment Regulatory Organization Trade Resumption - NGEN

Canada NewsWire March 21, 2024

NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING

Canada NewsWire March 21, 2024

Canadian Investment Regulatory Organization Trading Halt - NGEN

Canada NewsWire March 21, 2024

NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company

Newsfile February 21, 2024

NervGen Pharma Grants Stock Options

Newsfile February 20, 2024

NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

Newsfile February 15, 2024

NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates

Newsfile November 9, 2023

Neuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy Kawasaki

Newsfile November 8, 2023

NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury

Newsfile October 23, 2023

NervGen Pharma Appoints John Ruffolo to Board of Directors

Newsfile October 17, 2023

NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

Newsfile September 25, 2023

NervGen Pharma to Present at 2023 International Spinal Research Trust Network Meeting

Newsfile September 11, 2023

NervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment Conference

Newsfile September 5, 2023

NervGen Pharma to Present on its Drug Candidate NVG-291 and Spinal Cord Injury at Investor Conference

Newsfile August 22, 2023

NervGen Pharma Reports Q2 2023 Financial Results and Operational Updates

Newsfile August 9, 2023

NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval

Newsfile August 8, 2023

NervGen Pharma to receive US$3M for spinal cord injury study

Jonathon Brown June 27, 2023

NervGen Pharma to Receive More than US$3 Million from Wings for Life to Support Upcoming Clinical Study in Spinal Cord Injury

Newsfile June 27, 2023

NervGen Pharma to Present at Upcoming Investor Conferences

Newsfile June 20, 2023

NervGen Pharma Extends the Expiry Date of Certain Stock Options

Newsfile June 2, 2023